Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint - Marketscreener.com
| 278650 Stock | KRW 2,135 50.00 2.29% |
About 61% of KNOTUS CoLtd's investor base is looking to short. The analysis of current outlook of investing in KNOTUS CoLtd suggests that many traders are alarmed regarding KNOTUS CoLtd's prospects. The current market sentiment, together with KNOTUS CoLtd's historical and current headlines, can help investors time the market. In addition, many technical investors use KNOTUS CoLtd stock news signals to limit their universe of possible portfolio assets.
KNOTUS |
Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint Marketscreener.com
Read at news.google.com
 |
KNOTUS CoLtd Fundamental Analysis
We analyze KNOTUS CoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of KNOTUS CoLtd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of KNOTUS CoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
KNOTUS CoLtd is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
KNOTUS CoLtd Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with KNOTUS CoLtd stock to make a market-neutral strategy. Peer analysis of KNOTUS CoLtd could also be used in its relative valuation, which is a method of valuing KNOTUS CoLtd by comparing valuation metrics with similar companies.
Peers
KNOTUS CoLtd Related Equities
| 225220 | Genolution | 2.39 | ||||
| 293780 | AptaBio Therapeutics | 0.30 |
Complementary Tools for KNOTUS Stock analysis
When running KNOTUS CoLtd's price analysis, check to measure KNOTUS CoLtd's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy KNOTUS CoLtd is operating at the current time. Most of KNOTUS CoLtd's value examination focuses on studying past and present price action to predict the probability of KNOTUS CoLtd's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move KNOTUS CoLtd's price. Additionally, you may evaluate how the addition of KNOTUS CoLtd to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |